Swiss National Bank Sells 4,100 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Swiss National Bank lessened its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 3.6% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 111,300 shares of the specialty pharmaceutical company’s stock after selling 4,100 shares during the period. Swiss National Bank owned 0.18% of Jazz Pharmaceuticals worth $13,818,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Envestnet Asset Management Inc. raised its stake in Jazz Pharmaceuticals by 36.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 90,742 shares of the specialty pharmaceutical company’s stock valued at $11,175,000 after purchasing an additional 24,443 shares during the period. Townsquare Capital LLC raised its position in shares of Jazz Pharmaceuticals by 79.5% during the fourth quarter. Townsquare Capital LLC now owns 3,540 shares of the specialty pharmaceutical company’s stock valued at $436,000 after buying an additional 1,568 shares during the last quarter. Barclays PLC raised its position in shares of Jazz Pharmaceuticals by 70.2% during the fourth quarter. Barclays PLC now owns 66,728 shares of the specialty pharmaceutical company’s stock valued at $8,216,000 after buying an additional 27,518 shares during the last quarter. Mariner LLC lifted its holdings in shares of Jazz Pharmaceuticals by 33.9% in the fourth quarter. Mariner LLC now owns 26,803 shares of the specialty pharmaceutical company’s stock worth $3,301,000 after buying an additional 6,782 shares in the last quarter. Finally, Evergreen Capital Management LLC boosted its position in shares of Jazz Pharmaceuticals by 7.1% during the fourth quarter. Evergreen Capital Management LLC now owns 4,097 shares of the specialty pharmaceutical company’s stock worth $505,000 after acquiring an additional 273 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JAZZ. Morgan Stanley reduced their price target on shares of Jazz Pharmaceuticals from $165.00 to $162.00 and set an “overweight” rating on the stock in a report on Wednesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Royal Bank Of Canada decreased their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a “buy” rating and a $152.00 price target for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $181.43.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer owned 436,973 shares of the company’s stock, valued at $47,031,403.99. This represents a 0.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Trading Down 0.4%

JAZZ stock opened at $116.67 on Friday. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The stock has a market capitalization of $7.08 billion, a price-to-earnings ratio of -17.34, a price-to-earnings-growth ratio of 7.53 and a beta of 0.34. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The firm’s fifty day simple moving average is $111.69 and its two-hundred day simple moving average is $117.31.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.30 earnings per share. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.